Evidence map›Paper›PMID 40229393›Full record

ArticleScientific reports2025

Rapid formulation of a genetically diverse phage cocktail targeting uropathogenic Escherichia coli infections using the UTI89 model.

Pattida Kongsomboonchoke, Panupon Mongkolkarvin, Patiphan Khunti, Jarukit Vijitphichiankul, Poochit Nonejuie, Parameth Thiennimitr, Vorrapon Chaikeeratisak

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Bacteriophage-mediated reduction of uropathogenicbioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pattida KongsomboonchokeBiotechnology program, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
Panupon MongkolkarvinDepartment of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Patiphan KhuntiDepartment of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
Jarukit VijitphichiankulDepartment of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
Poochit NonejuieCenter for Advanced Therapeutics, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand.
Parameth ThiennimitrDepartment of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Vorrapon ChaikeeratisakDepartment of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand. vorrapon.c@chula.ac.th.

Funding

Faculty of Medicine, Chiang Mai University MIC 132/2567Fundamental Fund 2023, Chiang Mai University FF66/065
6 · The paper itself

Abstract

Urinary tract infections are commonly caused by uropathogenic Escherichia coli (UPEC). Due to the emergence of multidrug-resistant UPEC, rendering antibiotic treatment ineffective, phage combination-based therapy has been proposed as a potential alternative. Here, we present a formulation of a genetically diverse phage-derived cocktail that is rapidly customized for UPEC using E. coli UTI89 as a model strain. Through our rapid selection and combination of four phages against UPEC strain UTI89 (SR01, SR02, SR04, and Zappy) from our library, the combination of two lytic phages, SR02 and SR04, exhibits the strongest suppression of bacterial growth for at least 16 h, with no emergence of phage resistance observed in vitro. Phage SR02 undergoes subcellular activity for 25 min, producing approximately 106 progeny particles per cell, while SR04 completes its replication cycle in 20 min, generating around 564 progeny particles per cell. These two novel phages are genetically diverse, and their cocktail exhibited potent suppression of bacterial growth, independent of multiplicities of infection (MOIs), significantly reducing the viable bacterial counts after treatment in vitro. The phage cocktail has low immunogenicity and does not induce any proinflammatory gene responses in human bladder uroepithelial cells. Moreover, the cocktail effectively eradicates the invading UPEC strain UTI89 in the uroepithelial cells at a comparable level to that of phage SR04 alone, likely releasing some immunostimulatory agents that, in turn, trigger upregulation of MIP-3 and IL-8 genes. Altogether, this study offers an alternative pipeline for rapidly formulating genetically diverse phage-derived cocktails, which is specifically customized for targeted bacteria.

Indexed as

BacteriophagesEscherichia coli InfectionsPhage TherapyUrinary Tract InfectionsUropathogenic Escherichia coliHumansMultidrug-resistant (MDR) bacteriaPhage cocktail, drug resistance, disease-free and overall survivalPhage therapyUrinary tract infection (UTI)Uropathogenic Escherichia coli (UPEC)

Identifiers

PMID40229393
PMCPMC11997193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.